The Priority Review

Tag

C3 Glomerulopathy

1 story

  1. Clinical trials

    Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients

    The study, titled PRESERVE, plans to enroll 30 participants and has a planned start date of January 21, 2027. It aims to assess the efficacy and safety of pegcetacoplan for preventing recurrent C3G or primary IC-MPGN, with a planned primary completion date of January 17, 2031.